Search Medical Condition
Please enter condition
Please choose location from dropdown

Atco, New Jersey Clinical Trials

A listing of Atco, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (111) clinical trials

Observational Study of Obstructive Lung Disease (NOVELTY)

The NOVELTY study is a multi-country, multicentre, observational, prospective, longitudinal cohort study which will include patients with a physician diagnosis, or suspected diagnosis, of asthma and/or COPD. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. All patients enrolled in the NOVELTY study ...

Phase N/A

0.0 miles

Learn More »

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

This will be an open-label, uncontrolled study which will enroll completers from Study 31-08-250 and new subjects not participating in Studies 250. The treatment history of subjects prior to enrolment in the open-label study will vary according to the design of the pivotal double-blind study (i.e 31-08-250). This open-label study ...

Phase

3.65 miles

Learn More »

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.

Phase

3.96 miles

Learn More »

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with moderate and severe hepatic impairment.

Phase

3.96 miles

Learn More »

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Phase

3.96 miles

Learn More »

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

This study will be a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that requires continuous, around-the-clock (ATC) opioid treatment. The study will comprise 5 phases: a Screening Phase (up to 2 ...

Phase

3.96 miles

Learn More »

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Disorder (MDD).

Phase

3.96 miles

Learn More »

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

This multicenter study will assess the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.

Phase

3.96 miles

Learn More »

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia

Phase

3.96 miles

Learn More »

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia

Phase

3.96 miles

Learn More »